Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This study tests whether a special PET scan (68Ga-CTR-FAPI) can help surgeons remove all medullary thyroid cancer during the first surgery, aiming for a cure. About 150 newly diagnosed patients will be split into two groups: one gets surgery guided by the new scan, the other gets…

This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…

This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow sur…

This phase 3 trial tests whether a shorter, higher-dose radiation schedule (3 weeks) is as safe and effective as the standard 5-week schedule for women with high-risk breast cancer who have had a mastectomy and immediate implant reconstruction. The study will enroll 506 women and…

This study tests whether using advanced brain network mapping (connectome-guided navigation) during surgery can better preserve functions like speech and movement in people with brain tumors in critical areas. Two hundred participants will be randomly assigned to either this new …

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests whether adding an immunotherapy drug called adebrelimab to chemotherapy, with or without radiation, before surgery can help eliminate HER2-negative locally advanced breast cancer. About 170 women aged 18-70 will participate. The main goal is to see if the cancer …

This phase 2 trial tests whether adding a PD-L1 antibody (adebrelimab) to a three-drug chemotherapy regimen (vinorelbine, cyclophosphamide, capecitabine) and either early or delayed radiotherapy can help control brain tumors in people with advanced HER2-negative breast cancer. Ab…

This study looks at whether adding a new anti-tumor drug to standard radiation therapy can help control advanced breast cancer that has spread to the brain. About 100 adults with this condition will be observed to see how long the cancer stays under control and if the treatment i…

This Phase II trial tests whether adding a PD-L1 antibody (adebrelimab) to a specific chemotherapy regimen (VEX) — with or without radiation — can delay cancer growth in people with advanced triple-negative breast cancer. About 150 participants will be randomly assigned to one of…

This study looks at whether using radiotherapy before immunotherapy can help control advanced breast cancer that has spread or cannot be removed by surgery. About 150 adults who have already had radiotherapy will receive immunotherapy, and researchers will track how long it takes…

This study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to …

This phase 2 trial tests whether giving a drug called anlotinib (which cuts off tumor blood supply) along with immunotherapy (penpulimab) and radiation before surgery can improve outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. The study will enroll 30 ad…

This early-phase study tests an experimental therapy called V001 Injection, which aims to create cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to chec…

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them fro…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This early-phase study tests a new treatment called GC511B for adults with small cell lung cancer that has come back or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cel…

This study tests a combination of fruquintinib (a drug that blocks blood vessel growth to tumors) and chemotherapy (albumin-paclitaxel), with or without a PD-1 antibody, for people with advanced stomach or gastroesophageal junction cancer whose first PD-1 treatment stopped workin…

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 61 participants will receive the drug combination before and after sur…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination treatment …

This study tests a new treatment for advanced ovarian cancer patients who have a lot of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting special immune cells called SK-NK cells directly into the abdomen once a week for …

This Phase 2 trial tests whether trastuzumab rezetecan (SHR-A1811) works better than standard chemotherapy for people with HER2-Low breast cancer that has spread and is causing severe organ problems (visceral crisis). About 184 participants will receive either the new drug or a s…

This study tests whether adding the immunotherapy drug tislelizumab after surgery can help prevent lung cancer from coming back in people with high-risk stage I non-small cell lung cancer. About 108 adults whose tumors are 2–4 cm and have certain high-risk features will receive e…

This study tests whether adding the targeted drug anlotinib to whole-brain radiation helps control brain tumors better than radiation alone in people with small cell lung cancer. About 134 participants with up to 10 brain metastases will be enrolled. The goal is to see if the com…

This phase 2 trial tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help people with extensive-stage small cell lung cancer (SCLC) stay progression-free longer. Twenty adults who have not yet been treated for their advanced SCLC will receive t…

This phase 2 trial is testing two oral drugs, fuzuloparib and apatinib, given before surgery to women with a specific genetic type (HRD-positive) of advanced ovarian cancer. The goal is to shrink tumors enough for complete surgical removal, potentially improving outcomes and avoi…

This study looks at whether giving the drug tislelizumab before surgery can help people with a certain type of colorectal cancer (dMMR/MSI-H). About 30 adults with stage II or III cancer will get three doses of the drug, then have surgery. Researchers will check if the cancer dis…

This study is for women with advanced breast cancer that has spread to nearby lymph nodes. After initial chemotherapy, doctors will adjust the next steps—surgery and radiation—based on how much cancer remains. The goal is to see if this personalized approach can help people live …

This early-phase trial tests a new cell therapy called anti-PSMA CAR NK cells in 10 people with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that no longer responds to hormone therapy. The treatment uses immune cells engineered to target a pr…

This early-phase trial is testing a new drug called CREPT-618 in 13 adults with advanced liver cancer who have not responded to standard treatments. The drug works by targeting a gene called CREPT, which may help control tumor growth. The main goals are to check safety, find the …

This large phase 3 study is testing different combinations of chemotherapy, radiation, immunotherapy, and targeted drugs given before surgery for esophageal cancer. The goal is to find which approach works best to improve survival. The trial will enroll 2,000 adults with stage I …

This study is looking at the best way to treat esophageal cancer that cannot be removed by surgery. It will follow 2,000 patients who receive chemoradiotherapy (radiation plus chemotherapy) along with possible immunotherapy or targeted drugs. The goal is to see which combinations…

This early-phase study tests a new treatment for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment uses specially engineered immune cells (CAR-NK cells) designed to find and attack cancer cells. The main goal is to check if the t…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to better fight canc…

This early-phase trial tests an inhaled mRNA vaccine called BMD006 in 83 people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-associated antigens. The study will check safety, tolerabili…

This study is testing a new way to deliver radiation for prostate and bladder cancers. The approach uses an MRI-guided machine to adapt the radiation dose in real time, giving a higher boost to the tumor while sparing nearby organs. Researchers want to see if this reduces side ef…

This study tests a new type of radiation therapy for prostate cancer that uses an MRI machine to guide the beam in real time. The goal is to deliver high doses of radiation more precisely to the tumor while sparing healthy tissue. The trial will enroll 50 men with localized or li…

This trial is testing a new type of radiation therapy given before surgery for retroperitoneal sarcoma, a rare cancer in the abdomen. The radiation is delivered in just five high-dose sessions, targeting the tumor and any nearby nodules. The goal is to see if this approach reduce…

This study tests a personalized vaccine called LK101, made from a patient's own tumor markers, combined with standard immunotherapy drugs (pembrolizumab, durvalumab, or tislelizumab) in 60 adults with advanced lung cancer. The goal is to see if the combination is safe and can hel…

This Phase 2 trial is testing whether adding an experimental immune therapy (Iparomlimab/Tuvonralimab) to standard chemoradiation can improve outcomes for 30 women with locally advanced cervical cancer. The treatment targets two immune checkpoints to help the body fight cancer. T…

This phase 2 trial tests whether adding an immune checkpoint inhibitor (a type of immunotherapy) to standard chemotherapy before surgery can improve outcomes for people with locally advanced colorectal cancer. About 170 participants will be randomly assigned to receive either the…

This phase 2 trial tests whether combining a liver-directed procedure (TACE) with two drugs—atezolizumab (immunotherapy) and bevacizumab (anti-angiogenic)—given before surgery can improve outcomes for patients with liver cancer at high risk of recurrence. About 30 adults with res…

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink liver tumors in people with colorectal cancer that has spread only to the liver and cannot be surgically removed. About 40 adults will receive the combination every 3 weeks for up to 8 cycles…

This phase 3 trial tests whether combining radiotherapy with the immunotherapy drug sintilimab can better prevent liver cancer from coming back after surgery, compared to the standard TACE procedure. The study enrolls 286 adults with high-risk features like narrow surgical margin…

This phase 2 trial is testing a combination of low-dose cytarabine (a chemotherapy drug) and thalidomide in 50 adults with untreated Langerhans cell histiocytosis (LCH), a rare disease where immune cells build up and damage tissues. Participants receive up to 24 cycles of treatme…

This phase 2 trial tests whether a combination of lenalidomide and dexamethasone can control Rosai-Dorfman disease, a rare condition causing swollen lymph nodes and tissue inflammation. About 40 adults who are newly diagnosed or have not responded to prior treatments will receive…

This phase 2 trial is testing a combination of three drugs—nimotuzumab, toripalimab, and chemotherapy (gemcitabine/cisplatin)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults to see how well the combo shrinks tum…

This early-stage trial is testing a single infusion of cells from umbilical cord blood (called XJ-MK-002) in 16 cancer patients whose platelet counts have dropped due to chemotherapy or other cancer treatments. The main goal is to see if the treatment is safe and tolerable, and t…

This study is testing whether a quick lab test called MiniPDX can help doctors choose the best chemotherapy drugs for people with bile duct cancer after surgery. The test measures how sensitive a patient's tumor cells are to different drugs in just 7 days. Researchers will follow…

This study is testing a new radioactive tracer called Al18F-octreotide for PET/CT scans in people with suspected or confirmed SSTR-positive tumors. The goal is to see if this tracer can more accurately detect these tumors. About 400 participants will receive an injection of the t…

This study is testing a new, non-invasive urine test that looks for a protein called CREPT in cells shed from the bladder. The goal is to see if this test can accurately detect bladder cancer and monitor if it comes back after treatment, potentially replacing uncomfortable and in…

This trial tests whether a traditional Chinese herbal plaster called Gutong Plaster, applied to specific acupoints, can improve pain relief and reduce opioid use in adults with moderate to severe cancer pain. Participants receive either the real plaster or a placebo alongside sta…

This study tests a symptom management program for 300 esophageal cancer patients after surgery. The program uses patient feedback to guide care and aims to reduce common problems like reflux, trouble swallowing, and eating difficulties. Participants use a smartphone app to report…

This study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…

This study explores whether advanced PET/CT scans using special tracers can predict how well patients with aggressive lymphoma will respond to treatment and their long-term outlook. Researchers will inject two types of imaging agents—FAPI and Grazytracer—to visualize the tumor's …

This observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI…

This study looks back at patients with advanced squamous non-small cell lung cancer who received tislelizumab combined with chemotherapy in a previous trial. Researchers want to see how long patients lived and find out who benefits most from this treatment. The goal is to better …

This study looks at whether proteins in urine can help doctors predict how patients with advanced colorectal cancer will respond to treatment given before surgery. Researchers will collect urine samples from 400 participants before and after therapy and use advanced technology to…

This study follows 500 lung cancer patients who received immunotherapy before their main treatment. Researchers want to see whether surgery (removing part or all of a lung) or non-surgery options like radiation lead to better long-term outcomes. The goal is to find the best appro…